The mission of InVivo Therapeutics is to provide society with superior neurological products and services by delivering novel approaches to the treatment of disease that will improve the quality of life and satisfy the needs of those who live with spinal cord injury. We also seek to empower our employees to create new treatment options for spinal cord injuries with the expectation that they will have the opportunity to make a difference in the lives of all people impacted by these injuries.
Our business is preserving and improving human life. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction.
We recognize that our ability to excel and to most competitively meet society’s and customers’ needs depends on the integrity, knowledge, imagination/creativity, skill, diversity, practicality and teamwork of our employees, and we value these qualities above all else. To this end, we strive to create an environment of mutual respect, encouragement and teamwork—an environment that rewards commitment and performance and is responsive to the needs of our employees and their families.
Dr. Langer was awarded the 2006 National Medal of Science by President George W. Bush.
InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research
Our business is preserving and improving human life. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction.
We recognize that our ability to excel and to most competitively meet society’s and customers’ needs depends on the integrity, knowledge, imagination/creativity, skill, diversity, practicality and teamwork of our employees, and we value these qualities above all else. To this end, we strive to create an environment of mutual respect, encouragement and teamwork—an environment that rewards commitment and performance and is responsive to the needs of our employees and their families.
Dr. Langer was awarded the 2006 National Medal of Science by President George W. Bush.
InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research
Location: United Kingdom, England, Cambridge
Employees: 11-50
Phone: +1 617-863-5500
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Montrose C... | montroseca... |
Mentions in press and media 12
| Date | Title | Description |
| 05.02.2018 | InVivo makes it official: Richard Toselli becomes president and CEO, joins board | InVivo Therapeutics, which specializes in spinal cord injuries, named Richard Toselli, M.D., as its president and chief executive. Toselli, who has been acting CEO since December, was also appointed to the company’s board. Sponsored by Agil... |
| 05.02.2018 | InVivo makes it official: Richard Toselli becomes president and CEO, joins board | InVivo Therapeutics, which specializes in spinal cord injuries, named Richard Toselli, M.D., as its president and chief executive. Toselli, who has been acting CEO since December, was also appointed to the company’s board. The move comes ju... |
| 21.11.2016 | Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’ | This is one in a series of occasional updates on the lives of people featured by STAT during our first year. Jesi Stracham used to captivate biotech investors and inadvertently move markets with social media posts documenting her dogged que... |
| 18.05.2015 | InVivo reports mixed results in spinal scaffold trial | InVivo Therapeutics (OTC:NVIV) said the 1st acute spinal cord injury patient implanted with its investigational neuro-spinal scaffold has shown some improvement, but that a 2nd patient remains paralyzed below the waist, leading investors to... |
| 14.11.2014 | InVivo shares soar on spinal cord study update | InVivo Therapeutics (OTC:NVIV) shares soared more than 40% this week after Arizona doctors confirmed they had treated the 1st patient in a study of the company’s experimental bio-scaffolding device for acute spinal cord injuries. The stock,... |
| 09.12.2013 | MIT Professor Working to Close Wounds Inside the Body with Fresh $10.8M Series A | MIT Professor Robert Langer has launched yet another company, this time with the help of $10.8 million in Series A funding. Gecko Biomedical debuted Monday in France, and is working to create a synthetic, biodegradable adhesive that can clo... |
| 10.09.2013 | InVivo Therapeutics plunges again as interim CFO quits after 2 weeks | InVivo Therapeutics (OTC:NVIV) shares plunged some 22% today after the medical device company reported that its interim CFO, appointed 2 weeks ago after the sudden departure of CEO & CFO Frank Reynolds, had resigned effective immediatel... |
| 23.08.2013 | InVivo CEO & CFO Reynolds resigns citing medical condition | InVivo Therapeutics (OTC:NVIV) is getting a top-line shuffle after chairman, CEO and CFO Francis Reynolds resigned suddenly due to a "medical condition." The company named finance director Sean Moran as acting CFO, effective immed... |
| 05.06.2013 | InVivo tackles debt, aims for up-listing to a national exchange | Massachusetts-based spinal devices maker InVivo Therapeutics (OTC:NVIV) hopes to up-list to a national stock exchange now that it’s has paid down significant debts. Through calls for the early exercise of warrants InVivo fully eliminated th... |
| 16.10.2012 | Johnson & Johnson hits 52-week high on boosted earnings forecast | Wall Street Beat | Shares of Johnson & Johnson (NYSE:JNJ) surged to a 52-week high today after the healthcare conglomerate boosted its 2012 earnings forecast after reporting a solid, Street-beating quarter (and despite a nearly 18% bottom-line slide). JNJ... |
Show more